While clinical data regarding YY2 are still limited, C343R, G317C, and K263N mutations in zinc‐finger domains of YY2 as potentially found in cancer patients cancelled the YY2 regulatory effect on SLC7A11 expression. This evidence concerns the gene YY2 and cancer.